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Beneficial Effects of Conversion From Cyclosporine to
Azathioprine on Fibrinolysis in Renal Transplant Recipients
Marinus A. van den Dorpel, Arie J. Man in’t Veld, Marcel Levi, Jan Wouter ten Cate, Willem Weimar
Abstract—Cyclosporin A (CsA) has been implicated as one of the factors contributing to the high cardiovascular morbidity
and mortality after renal transplantation. This may be mediated by either a high prevalence of conventional risk factors
for atherosclerosis, such as hypertension, hypercholesterolemia, and diabetes mellitus, or by impairment of the
fibrinolytic activity evoked by CsA, possibly through interference with prostanoid metabolism. We therefore assessed
the impact of conversion of CsA to azathioprine immunosuppressive treatment on parameters of fibrinolytic activity and
plasma concentration of the prostanoids prostaglandin E2 and thromboxane B2 in 18 stable renal transplant recipients.
During CsA, mean arterial pressure and serum creatinine were significantly higher than during azathioprine
(116615 mm Hg versus 106613 mm Hg, P50.0003; and 147634 mmol/L versus 127635 mmol/L, P50.002;
mean6SD). On conversion, the plasma tissue plasminogen activator activity increased from 1.2 (1.1 to 1.7; median,
95% CI) to 1.8 (1.6 to 2.0) IU/mL (P50.011), without a significant change of the plasminogen activator antigen
concentration. This was associated with a substantial decrease in plasminogen activator inhibitor-1 activity from 10.4
(8.5 to 16.7) to 6.4 (5.6 to 9.2) IU/mL (P50.009). Furthermore, plasma levels of prostaglandin E2 and thromboxane B2
markedly decreased (from 9.7 [7.4 to 12.9] to 4.6 [4.3 to 8.1] pg/mL, P50.0006; and from 106.1 [91.7 to 214.2] to 70.2
[50.3 to 85.6] pg/mL, P50.002, respectively). During CsA, but not azathioprine, plasma tissue plasminogen activator
antigen and plasminogen activator inhibitor-1 levels correlated significantly with prostaglandin E2 (r50.53, P50.02;
and r50.60, P50.008, respectively), and thromboxane B2 (r50.75, P50.0001; and r50.77, P50.0001, respectively)
levels. In conclusion, CsA induced substantial impairment of fibrinolytic activity, which recovered after conversion to
azathioprine. The impaired fibrinolysis observed during CsA treatment may be caused by modulation of eicosanoid
production or metabolism in vascular endothelial cells and possibly contributes to the high incidence of cardiovascular
disease after kidney transplantation. (Arterioscler Thromb Vasc Biol. 1999;19:1555-1558.)
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In renal transplant recipients the morbidity and mortalitycaused by atherosclerosis are substantially higher com-
pared with the normal population.1 Cardiovascular disease
accounts for up to 40% of deaths after renal transplantation,
and there is increasing evidence that patients who are treated
with cyclosporin A (CsA) are at high risk.2–4 Hypertension
and hyperlipidemia are undoubtedly involved; however, dis-
turbances in the fibrinolytic system appear to play an impor-
tant role in the pathogenesis of atherosclerosis and thrombo-
sis as well.5,6 Impaired activity of the fibrinolytic system
mostly results from excess plasminogen activator inhibitor-1
(PAI-1), and less commonly from reduced release of tissue or
urokinase-type plasminogen activator, and has been associ-
ated with the use of the immunosuppressant CsA.7 Because of
endothelial cell damage and toxicity, CsA has been shown to
increase the plasma levels of PAI-1, which results in de-
creased fibrinolytic activity.8 CsA-induced disturbances in
prostanoid metabolism may also be implicated in the patho-
genesis of the reduced fibrinolytic activity.9
We therefore hypothesized that conversion from CsA to
azathioprine (AZA) as long-term immunosuppressive therapy
would potentially ameliorate fibrinolytic activity. In the first
prospective controlled study with paired observations to
address this issue, we compared several parameters of the
fibrinolytic system in renal transplant patients during CsA
and after conversion to AZA treatment to determine the
reversibility of the possible harmful effects on the fibrinolytic
axis of long-term CsA. Plasma levels of prostaglandin E2
(PGE2) and thromboxane B2 (TXB2) were determined to
assess whether CsA-induced interference with prostanoid
metabolism is associated with impaired fibrinolysis, as has
been suggested by others.9
Methods
Patients
Patients were recruited among renal transplant recipients who had
been enrolled in a prospective randomized clinical trial, which was
designed to evaluate the effects of 2 different immunosuppressive
Received June 17, 1997; revision accepted November 5, 1998.
From the Department of Internal Medicine I (M.A.D., A.J.M.V., W.W.), University Hospital Rotterdam, and the Department of Internal Medicine
(M.L., J.W.C.), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Correspondence to M.A. van den Dorpel, MD, PhD, Department of Internal Medicine, St. Clara Hospital Rotterdam, Olympiaweg 350, 3078 HT
Rotterdam, The Netherlands.
© 1999 American Heart Association, Inc.
Arterioscler Thromb Vasc Biol. is available at http://www.atvbaha.org
1555
regimens, ie, prednisone combined with CsA or with AZA, on
long-term graft function and incidence of rejection episodes. In this
trial all CsA-treated renal transplant recipients, between 18 and 65
years of age, and 6 months or longer after transplantation, were
randomly allocated to either continuation of CsA treatment or
conversion from CsA- to AZA-based immunosuppression. Patients
with diabetes mellitus, proteinuria of .3 g/d, acute graft rejection in
the previous 3 months, or histological evidence of chronic graft
rejection were excluded. The first 18 consecutive patients fulfilling
these criteria and willing to give written informed consent were
included in the present study, which was approved by the Medical
Ethics Committee of the University Hospital Rotterdam.
Study Design
All patients were examined the first time during CsA, and the second
time during AZA. After the first examination, AZA was started at a
dose of 2 mg/kg daily. Two weeks later the CsA dose was reduced
to 50%, followed by discontinuation after another 2 weeks. The
second examination took place 12 weeks after withdrawal of CsA.
Patients used the same dose of prednisone (range, 7.5 to 12.5 mg
daily) during both examinations. All antihypertensive medication
(b-blockers in 13 patients and calcium-channel blockers in 8
patients) was discontinued at least 3 days before both study sessions.
All medication influencing the activity of the fibrinolytic system was
discontinued at least 3 days before the studies. Patients treated with
salicylic acid derivatives were excluded from this study.
Blood Sampling and Assays
On both study days an intravenous catheter (Venflon, Viggo Spec-
tramed) was inserted in the antecubital vein of the nondominant arm.
After 30 minutes of rest in the supine position, venous blood samples
were drawn in the appropriate anticoagulant. Platelet-poor plasma
was obtained by immediate centrifugation at 1600g for 20 minutes at
4°C. All serum and plasma samples were stored at 270°C until
assayed.
Tissue plasminogen activator (tPA) activity was measured by an
amidolytic assay.10 Briefly, 25 mL of plasma was mixed to a final
volume of 250 mL with 0.1 mol/L Tris-HCl, pH 7.5, 0.1% (vol/vol)
Tween-80, and 0.3 mmol/L S-2251 (Chromogenix). The results are
expressed as international units per milliliter. PAI-1 activity was
measured with an amidolytic assay,11 in which the samples were
incubated with an excess of tPA (40 IU/mL) for 10 minutes at room
temperature. The residual tPA activity was determined by incubation
with 0.13 mmol/L plasminogen (Chromogenix), 0.12 mg/mL cyano-
gen bromide-digested fibrinogen fragments (tPA stimulator, Chro-
mogenix), and 0.1 mmol/L S-2251. The PAI-1 activity in the sample
is inversely proportional to the plasmin generated in the mixture,
determined by the conversion of the chromogenic substrate. Results
are expressed in international units, where 1 IU is the amount of
PAI-1 that inhibits 1 IU tPA. tPA antigen and PAI-1 antigen were
assayed with ELISAs12 (Asserchrom t-PA, Diagnostica Stago, and
PAI-1-ELISA kit, Monozyme, respectively). All results are ex-
pressed in nanograms per milliliter.
To assess plasmin generation in vivo, concentrations of plasmin
complexed to a2-antiplasmin (PAP complexes) were measured by a
specific RIA.13 Briefly, specific monoclonal antibodies, raised
against inactivated and complexed a2-antiplasmin, were coupled to
Sepharose beads and incubated with plasma. After washing the
Sepharose with PBS, bound complexes were subsequently incubated
with 125I-labeled monoclonal antibodies against plasmin. After an-
other washing step, Sepharose-bound radioactivity was measured. As
standards, serial dilutions of plasma in which a maximal amount of
PAP complexes was generated by incubation with 2-chain urokinase
(Choay) were used. The results are expressed as nanomoles per liter.
Our laboratory’s normal values of the various components of the
fibrinolytic system were determined in age-matched healthy
volunteers.
PGE2 and TXB2 were measured with competitive enzyme immu-
noassays (Cayman Chemical), using a monoclonal antibody against
PGE2 and specific polyclonal anti-TXB2 antibodies, respectively.14
Blood 12-hour trough CsA levels were determined with a polyclonal
immunoassay (CycloTrac SP, Incstar).
Statistics
All data are presented as median6SD, unless indicated otherwise.
Paired Student’s t test and Wilcoxon’s signed rank test were used as
appropriate for assessing the statistical significance of the differences
between CsA and AZA therapy. The relationships between different
parameters were calculated with Pearson’s correlation coefficient.
Results
Clinical Characteristics
During CsA, mean arterial pressure was significantly higher
(116615 mm Hg versus 106613 mm Hg; mean6SD;
P50.0003), and serum creatinine was significantly higher
(147634 mmol/L versus 127635 mmol/L; mean6SD;
P50.002), than during AZA. Body mass index did not
change on conversion. The daily dose of prednisone was
identical during both treatments (Table 1). No acute rejection
episodes occurred between both examination sessions.
Fibrinolysis and Prostanoids
Conversion from CsA to AZA was followed by an increase in tPA
activity from 1.2 (1.1 to 1.7) IU/mL to 1.8 (1.6 to 2.0) IU/mL
(P50.011; normal value, 1.7 [1.4 to 2.0] IU/mL). As shown in
Figure 1A, the increase in tPA activity appeared to be caused by a
reduction in PAI-1, as reflected by a decrease in plasma levels of
PAI-1 antigen (Figure 1D) and associated activity (Figure 1C), and
virtually unchanged levels of tPA antigen (Figure 1B). The slight
decrease in tPA antigen levels can be readily explained by the fact
that this assay also measures tPA–PAI-1 complexes, and will
therefore be somewhat affected by decreasing PAI-1 levels. Plasma
PAI-1 activity and antigen levels decreased from 10.4 (8.5 to 16.7)
to 6.4 (5.6 to 9.2) IU/mL (P50.009; normal, 7.7 [6.1 to 9.3]
IU/mL), and from 13.4 (9.5 to 18.2) to 8.8 (7.2 to 11.3) ng/mL
(P50.016; normal, 7.3 [5.9 to 8.7] ng/mL), respectively. The
enhancement of tPA activity resulted in an increase of plasmin
formation, as reflected by an increase in PAP complex levels from
3.4 (3.0 to 5.8) to 5.2 (4.1 to 6.4) nmol/L (P50.05; Table 2). Plasma
concentrations of both PGE2 and TXB2 were significantly lower
during AZA treatment (Table 2).
Correlation Between Prostanoids and
Fibrinolysis Parameters
During CsA but not AZA treatment, we observed strong positive
correlations between plasma levels of PAI-1 antigen and PGE2
(r50.60, P50.008; Figure 2, top left) and also between PAI-1
antigen and TXB2 (r50.77, P50.0001; Figure 2, top right). The
plasma concentration of tPA antigen was positively correlated to
TABLE 1. Patient Characteristics
CsA AZA
Sex, male/female 16/3
Age, y 41623
Time after transplantation, mo 2465 2765
Body mass index, kg/m2 24.963.5 24.963.3
Mean arterial pressure, mm Hg 116614 109612*
Glomerular filtration rate, mL/min 50614 57619*
Prednisone dose, mg/d 9.662.1 9.662.1
CsA dose, mg z kg21 z d21 5.561.7 z z z
AZA dose, mg z kg21 z d21 z z z 1.860.4
*P,0.05, CsA vs AZA, paired t test.
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plasma PGE2 (r50.53, P50.02) and plasma TXB2 (r50.75,
P50.0001; data not shown). Interestingly, TXB2 was negatively
correlated to tPA activity (r520.70, P50.001; Figure 2, bottom
left), which suggests that TXB2-induced elevation of PAI-1 inhibits
tPA antigen. This suggestion was supported by the negative corre-
lation between TXB2 and PAP-complex levels (r520.64,
P50.004; Figure 2, bottom right).
Discussion
The main finding to emerge from our study is that in renal
transplant recipients, the activity of the fibrinolytic system
increases substantially after conversion from CsA to AZA.
The reason for this improvement appears to be a decrease in
plasma PAI-1 levels. During CsA, but not AZA, we also
found strong correlations between plasma prostanoid levels
and several components of the fibrinolytic system.
In a number of studies, impaired fibrinolysis has been
associated with the development of acute atherothrombotic
events.5,6 We found that PAI-1 activity was significantly
higher during CsA, which resulted in a reduction of tPA
activity and subsequent plasmin formation as reflected by
decreased PAP complexes. This finding is in agreement with
data from a cross-sectional study, showing that in a group of
CsA-treated renal transplant recipients PAI-1 was higher than
in AZA-treated transplant recipients.15 The magnitude of the
increase of plasma PAI-1 we found during CsA is comparable
to the difference in PAI-1 levels between patients with an
uneventful course after myocardial infarction and patients
who had reinfarction.6
The mechanism of this CsA-associated impairment of fibri-
nolysis is not clear. A defective release of tPA and PAI-1 on
1-deamino-8-D-arginine vasopressin (DDAVP) stimulation was
reported in CsA-treated renal transplant recipients, although
basal tPA and PAI-1 levels were similar to those of AZA-treated
patients.16 The impaired DDAVP-induced release of tPA was
restored by fish-oil administration, suggesting that a CsA-
induced alteration in prostanoid metabolism may be related to
the impairment of fibrinolysis.
This hypothesis is supported by our finding that plasma PGE2
and TXB2 decreased markedly after conversion. This is in accor-
dance with other data showing that during CsA systemic and
intrarenal prostaglandin synthesis is disturbed.17,18 In addition, it has
been shown that changes in eicosanoid dynamics may significantly
affect vessel wall-related fibrinolytic activity.9 The notion that
alterations in prostanoid metabolism are involved in the attenuation
of fibrinolytic activity during CsA is further corroborated by our
finding that plasma PGE2 was closely correlated to plasma tPA
activity and PAI-1 antigen and activity levels. In addition, TXB2
was strongly negatively correlated to tPA activity and PAP com-
plexes, and positively correlated to PAI-1 antigen and PAI-1
Figure 1. Box whisker plots of plasma tPA activity
(tPA-Act; A), tPA antigen (tPA-Ag; B), PAI-1 activity
(PAI-1-Act; C), and PAI-1 antigen (PAI-Ag; D) dur-
ing CsA and AZA treatment. *Indicates P50.010;
#, not significant; †, P50.009; and ‡, P50.016;
CsA vs AZA by Wilcoxon’s signed rank test.
Figure 2. Scatterplots and linear regression lines with 95% CI
of relationship between plasma PGE2 or TXB2 and several com-
ponents of the fibrinolytic cascade during CsA treatment.
TABLE 2. Plasma Concentrations of PAP Complexes and
Prostanoids During CsA and AZA
Parameter CsA AZA P Value*
PAP, nmol/L 3.4 (3.0–5.8) 5.2 (4.1–6.4) 0.05
PGE2, pg/mL 9.7 (7.4–12.9) 4.6 (4.3–8.1) 0.006
TXB2 pg/mL 106.1 (91.7–214.2) 70.2 (50.3–85.6) 0.002
Data are given as median values (95% CI).
*Calculated by Wilcoxon’s signed rank test.
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activity. However, during AZA, no correlation between prostanoids
and fibrinolytic parameters was present, which may suggest that
after conversion the normal regulatory dynamics of fibrinolysis and
prostaglandin synthesis was restored.
It is tempting to speculate about alternative explanations
for the impairment of fibrinolysis during CsA. In vitro,
oxidized LDL is a potent stimulator of the release of PAI-1 by
cultured endothelial cells.19 Interestingly, we and others
recently found that during CsA treatment, LDL is more
oxidized, because of increased susceptibility to oxidation
both in vivo and in vitro.20,21 Therefore, it is conceivable that
oxidized LDL may enhance the release of PAI-1 in vivo,
resulting in reduced fibrinolytic activity.
The decrease in PAI-1 activity may also be associated with the
simultaneous fall in blood pressure after conversion.22 In a cross-
sectional study of healthy young men, the incidence of hypofibri-
nolysis caused by increased PAI-1 activity was increased in hyper-
tensive subjects.23 The association between hypertension and
impairment of fibrinolysis may be mediated by a third factor, eg,
hyperinsulinemia or insulin resistance.24 Other studies have dem-
onstrated significant correlations between hypertriglyceridemia
(which was also present during CsA), increased body weight, and
hypofibrinolysis caused by increased PAI-1.25
Finally, an alternative mechanism may proceed through the
LDL-receptor-related protein/a2-macroglobulin receptor,
which is involved in the internalization and intracellular
degradation of complexes of plasminogen activator and its
inhibitor PAI-1.26 CsA may lead to functional impairment of
this receptor, leading to decreased PAI-1 clearance and,
consequently, higher PAI-1 plasma levels.
The fact that all patients were examined during CsA first
may have influenced our study results. Because of the current
practice to use CsA as the initial immunosuppressive drug,
randomization to CsA or AZA first was not possible. There-
fore, a temporal bias cannot be completely excluded, al-
though the patients had a stable graft function and were on
average 24 months after transplantation.
In summary, we found that in renal transplant recipients,
conversion from CsA to AZA is accompanied by a substantial
enhancement of fibrinolytic activity. Our findings may contrib-
ute to the pathogenetic basis for the high incidence of cardio-
vascular disease after organ transplantation, which has been
associated with the long-term use of CsA.2–4 Whether the
positive effects of long-term treatment with CsA on graft
survival are outweighed by the negative effects on cardiovascu-
lar morbidity and mortality should be a topic for future studies.
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